Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2002

View Archived Issues

Research reveals mechanism of prostacyclin synthase gene transfer in injured vessels

Further benefit of atorvastatin found in dyslipidemic patients

HCT-1026 diminishes restenosis in an animal model of angioplasty

G-3139 and doxorubicin exhibit favorable interaction in breast cancer model

Cordase as a safe and effective alternative to surgery in Dupuytren's disease

Monotherapy with angiostatic steroid safe in patients with subfoveal AMD

Carotenoids appear to function as ocular antioxidants and to protect against AMD and cataracts

Nymox selects clinical Alzheimer's disease candidate

Posurdex provides higher and more sustained intravitreous drug levels than free dexamethasone

Genentech defines MTD for antiangiogenic antibody fragment in AMD

Antiacne prodrug designed at Tamarkin as potentially safer and more effective than current therapies

Uncoupling protein 3 polypeptides for the treatment of obesity and diabetes

Beta3-adrenoceptor agonists with utility in type 2 diabetes

Antagonists of ETA and ETB receptors with potential utility in circulatory disorders

Gamma-amino acid compounds as GABA analogues with use in epilepsy, etc.

Inhibitors of the ileal bile acid transporter claimed for the treatment of atherosclerosis

Novuspharma describes preparation and use of antitumor compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...